Viewing nowValsartan Tablets 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Kookje Pharm Co., Ltd.

MFDS item code 200808198 · Notified 2008.07.28 · Insurance code 643703080
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to treat essential hypertension and effectively lowers blood pressure. It also helps alleviate symptoms in heart failure patients classified as NYHA class II to IV who are intolerant to ACE inhibitors. Additionally, it is used to reduce the risk of mortality in stable patients with left ventricular dysfunction or decreased contractile function after a myocardial infarction. Through these pharmacological actions, it aids in the management of heart-related diseases and improvement of patients' conditions.
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose, regardless of sex or race, is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with this medicine at 40 mg once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so use should be discontinued immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, as well as lactating women, should not take this medication. Administration is contraindicated in patients with severe liver dysfunction, certain liver diseases, severe kidney impairment, and a history of angioedema. Elderly patients or those with high serum potassium levels and mild to moderate liver dysfunction should be particularly cautious when administering this medication, starting with a low dose and gradually increasing it. Blood pressure may drop significantly during treatment, so if symptoms of dizziness or fainting occur, medical personnel should be notified immediately. Due to the risk of hyperkalemia, potassium-sparing diuretics or potassium supplements should be periodically monitored when taken together. When taken in conjunction with other antihypertensives or diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), caution is needed due to potential interactions that may affect blood pressure control or kidney function. During treatment, side effects such as headache, dizziness, fatigue, cough, and diarrhea may occur, and in the event of severe swelling or allergic reactions, the medication should be stopped immediately, and a doctor consulted. Patients with heart failure or after myocardial infarction may experience changes in kidney function, requiring regular kidney function tests. The safety and efficacy of this medication have not been established in children and adolescents, so it is not recommended for those under 18 years of age. In case of overdose, symptoms such as hypotension or reduced consciousness may present, and emergency treatment should be sought immediately; blood dialysis is not effective. Store the medication out of reach of children and do not transfer it to other containers. Caution is required while driving or operating machinery during treatment, as dizziness may occur.
headache
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is also important to keep it in a cool place, below 30 degrees Celsius, to maintain its effectiveness.
Oval film-coated tablet, orange with a gray tint
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Kookje Pharm Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.